Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918306 | 0.92 | CYSLTR2 (0.61) | CYSLTR2SLC6A5ALDH1A1 | |
| SCHEMBL13918309 | 0.92 | CYSLTR2 (0.68) | CYSLTR2ALDH1A1 | |
| SCHEMBL13918313 | 0.92 | CYSLTR2 (0.61) | CYSLTR2SLC6A5 | |
| SCHEMBL13918301 | 0.91 | CYSLTR2 (0.56) | CYSLTR2MRGPRX4SLC6A5ALDH1A1POLB | |
| SCHEMBL13918326 | 0.91 | CYSLTR2 (0.59) | CYSLTR2SLC6A5ALDH1A1 | |
| SCHEMBL4522542 | 0.91 | CYSLTR2 (0.63) | CYSLTR2SLC6A5ALDH1A1 | |
| SCHEMBL4522808 | 0.90 | CYSLTR2 (0.60) | CYSLTR2SLC6A5ALDH1A1POLB | |
| SCHEMBL4526968 | 0.90 | CYSLTR2 (0.59) | CYSLTR2SLC6A5ALDH1A1POLBIDH1 | |
| SCHEMBL4521709 | 0.90 | CYSLTR2 (0.59) | CYSLTR2SLC6A5ALDH1A1 | |
| SCHEMBL4520534 | 0.90 | CYSLTR2 (0.68) | CYSLTR2SLC6A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | CYSLTR2 1426/4885MRGPRX4 3412/4885SLC6A5 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.